| 1. |
- Gedda, Hans, et al.
(författare)
-
Energy redistribution during CO2 laser cladding
- 2001
-
Ingår i: Congress proceedings. - Orlando, Fla : Laser institute of America. - 912035730 ; , s. 549-558
-
Konferensbidrag (refereegranskat)abstract
- This paper examines the factors that effect the efficiency of the CO sub 2 -laser powder cladding process. By theoretical calculation and experimental work it has been possible to identify how much of the original laser energy contributes to the cladding process and how much is lost to the surrounding environment by reflection, radiation, convection etc. Every aspect of energy redistribution has been analysed and quantified and this has lead to a deeper understanding of the process. The paper concludes with a number of suggestions for improving the efficiency of blown powder laser cladding
|
|
| 2. |
- Gedda, Hans, et al.
(författare)
-
Energy redistribution during CO2 laser cladding
- 2002
-
Ingår i: Journal of laser applications. - : Laser Institute of America. - 1042-346X .- 1938-1387. ; 14:2, s. 78-82
-
Tidskriftsartikel (refereegranskat)abstract
- This article examines the factors that effect the efficiency of the CO sub 2 -laser powder cladding process. By theoretical calculation and experimental work it has been possible to identify how much of the original laser energy contributes to the cladding process and how much is lost to the surrounding environment by reflection, radiation, convection, etc. Every aspect of energy redistribution has been analyzed and quantified and this has led to a deeper understanding of the process. The article concludes with a number of suggestions for improving the efficiency of blown powder laser cladding.
|
|
| 3. |
- Persson, Mikael, et al.
(författare)
-
[Lu-177]pertuzumab : Experimental therapy of HER-2-expressing xenografts
- 2007
-
Ingår i: Cancer Research. - 0008-5472 .- 1538-7445. ; 67:1, s. 326-331
-
Tidskriftsartikel (refereegranskat)abstract
- Pertuzumab (Omnitarg) is a novel antibody against HER-2, domain II. HER-2 is a tyrosine kinase receptor that is overexpressed in several carcinomas, especially breast cancer. Pertuzumab, labeled with the low-energy beta emitter Lu-177, might be a candidate for targeted radiotherapy of disseminated HER-2-positive micrometastases. The radiolabeled antibody [Lu-177]pertuzumab showed favorable targeting properties in BALB/c (nu/nu) mice with HER-2-overexpressing xenografts. The absorbed dose in tumors was more than five times higher than the absorbed dose in blood and more than seven times the absorbed dose in any other normal organ. Experimental therapy showed that [Lu-177]pertuzumab delayed tumor progression compared with controls (no treatment, P < 0.0001; nonlabeled pertuzumab antibody, P < 0.0001; and Lu-177-labeled irrelevant antibody, P < 0.01). No adverse side effects of the treatment could be detected. Thus, the experimental results support the planning of clinical studies applying [Lu-177]pertuzumab for therapy.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Carlsson, Jörgen, et al.
(författare)
-
Conjugate chemistry and cellular processing of EGF-dextran
- 1999
-
Ingår i: Acta Oncologica. - 0284-186X .- 1651-226X. ; 38:3, s. 313-321
-
Tidskriftsartikel (refereegranskat)abstract
- Conjugates with specific binding to the epidermal growth factor receptor, EGFR, of interest for radionuclide based imaging and therapy were prepared using mouse epidermal growth factor, mEGF, and dextran. In one type of conjugate, mEGF was coupled to dextran by reductive amination in which the free amino group on the mEGF N-terminal reacted with the aldehyde group on the reductive end of dextran. The end-end coupled conjugate could be further activated by the cyanopyridinium agent CDAP, thereby introducing tyrosines to the dextran part. In the other type of conjugate, the cyanylating procedure using CDAP was applied, first to activate dextran and then allowing for the amino terminus of mEGF to randomly attach to the dextran. In the latter case, radionuclide-labelled tyrosines or glycines could be added in the same conjugation step. All types of mEGF-dextran conjugates had EGFR-specific binding since the binding could be displaced by an excess of non-radioactive mEGF. The conjugates were to a large extent internalized in the test cells and the associated radioactivity was retained intracellularly for different times depending on both the type of cells and conjugate applied. Different intracellular 'traffic routes' for the radionuclides are discussed as well as applications for both imaging and therapy.
|
|
| 7. |
- Carlsson, Jörgen, et al.
(författare)
-
Planning for intracavitary anti-EGFR radionuclide therapy of gliomas : Literature review and data on EGFR expression
- 2006
-
Ingår i: Journal of Neuro-Oncology. - : Springer Science and Business Media LLC. - 0167-594X .- 1573-7373. ; 77:1, s. 33-45
-
Tidskriftsartikel (refereegranskat)abstract
- Targeting with radionuclide labelled substances that bind specifically to the epidermal growth factor receptor, EGFR, is considered for intracavitary therapy of EGFR-positive glioblastoma multiforme, GBM. Relevant literature is reviewed and examples of EGFR expression in GBM are given. The therapeutical efforts made so far using intracavitary anti-tenascin radionuclide therapy of GBM have given limited effects, probably due to low radiation doses to the migrating glioma cells in the brain. Low radiation doses might be due to limited penetration of the targeting agents or heterogeneity in the expression of the target structure. In this article we focus on the possibilities to target EGFR on the tumour cells instead of an extracellular matrix component. There seems to be a lack of knowledge on the degree of intratumoral variation of EGFR expression in GBM, although the expression seemed rather homogeneous over large areas in most of the examples (n=16) presented from our laboratory. The observed homogeneity was surprising considering the genomic instability and heterogeneity that generally characterises highly malignant tumours. However, overexpression of EGFR is, at least in primary GBMs, one of the steps in the development of malignancy, and tumour cells that lose or downregulate EGFR will probably be outgrown in an expanding tumour cell population. Thus, loss of EGFR expression might not be the critical factor for successful intracavitary radionuclide therapy. Instead, it is likely that the penetration properties of the targeting agents are critical, and detailed studies on this are urgent.
|
|
| 8. |
|
|
| 9. |
- Gedda, Hans, et al.
(författare)
-
A process efficiency comparison of Nd:YAG and CO2 laser cladding
- 2002
-
Ingår i: Welding in the World. - 0043-2288 .- 1878-6669. ; 46:spec, s. 75-86
-
Tidskriftsartikel (refereegranskat)abstract
- Blown powder laser cladding is a cost effective way of producing a surface layer to withstand wear and corrosion. However, the cladding process is slow. Therefore is it of great interest to investigate how much of the laser power is used in the cladding process and how much is reflected etc. In this investigation an Nd:YAG and a CO2-laser have been compared as energy sources for the process. Every aspect of the energy redistribution during cladding has been analysed. The main energy loss to the process for both lasers is by reflection from the melt pool and the powder cloud. It was found that the Nd: YAG laser cladding process is approximately twice as energy efficient as the CO2 laser cladding process
|
|
| 10. |
|
|
